Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4678 is a member of the microRNA family—short, non-coding RNAs (typically 20–24 nucleotides) that regulate gene expression by targeting messenger RNAs (mRNAs) for degradation or translational repression[1][2][5][7]. MicroRNAs are synthesized through transcription by RNA polymerase II, cleaved in the nucleus by Drosha to form precursor miRNAs, exported to the cytoplasm, and further processed by Dicer to their mature forms; these are then loaded into Argonaute proteins to form the RNA-induced silencing complex (RISC), mediating repression of target mRNAs[2][3][7]. While miRNAs regulate diverse cellular processes—including cell differentiation, proliferation, survival, and development[6]—no specific biological role, disease association, or drug interaction for MIR4678 is currently reported[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 4678 (MIR4678).